Adding One Year of Palbociclib to Adjuvant Endocrine Treatment Does Not Improve OS or iDFS in High-Risk HR-positive, HER2-negative Primary Breast Cancer By Ogkologos - April 8, 2025 848 0 Facebook Twitter Google+ Pinterest WhatsApp Final survival results from the PENELOPE-B study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Belzutifan with Pembrolizumab for Adjuvant Treatment of Renal Cell Carcinoma How Decades of NCI Support Led to Groundbreaking Discoveries: The Story of Immune Checkpoint Inhibitors Adding Belzutifan to Pembrolizumab Prolongs DFS After Nephrectomy in Patients with ccRCC at Increased Risk for Recurrence MOST POPULAR New Study Shows Intermittent Fasting May Reduce Breast Cancer Risk and... January 26, 2021 County Denies Immunocompromised Employee’s Request to Work from Home During COVID-19 March 17, 2020 Exercise of Any Intensity Found to Provide Similar Benefits in Cancer... February 10, 2021 How Finding the Right Primary Care Physician During Cancer Has Helped... March 24, 2021 Load more HOT NEWS NCI Part of Federal Effort to Evaluate Antibody Tests for Novel... New Research Discovers How Scalp Cooling Helps Chemo Patients Keep Their... How I Navigated the Challenges of 2 Colorectal Cancer Diagnoses As... New ESMO President 2029-2030 Elected
